Breaking News

C2 Pharma Acquires Digoxin API Portfolio from Nobilus Ent

Secures long-term supply of this complex and essential API

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

C2 Pharma, a Luxemburg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, has acquired the Digoxin API product portfolio of Polish company, Nobilus Ent, self-developed and inherited from Roche/Galenus Mannheim. Through the agreement, C2 Pharma is the product owner, and Nobilus is a manufacturing partner and releasing entity for the API. Parallel manufacturing to ensure redundancy is supported by long-term partner, Laurus Labs, an India-based API manufacturer.  ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters